Indian startups Aarna.ml and Ahammune Biosciences have raised significant Series A funding to support their growth and innovation. Aarna.ml, which provides GPU-as-a-Service (GPUaaS) software, raised $6.7 million, while Ahammune Biosciences, focused on skin disease therapies, secured $5 million.
Aarna.ml raised $6.7 million in an extended Series A round led by Exfinity Venture Partners. This funding follows a previous $5.5 million round in October 2023 from investors like NVIDIA, LDV Partners, and 3Lines.
Aarna.ml helps GPUaaS providers and NVIDIA Cloud Partners manage their AI workloads. Its platform offers multi-tenant GPU instances with full isolation, allowing companies to use a shared pool of GPUs efficiently.
The new funds will be used to enhance product development and expand the company’s reach. "Exfinity’s expertise will help us grow and make a bigger impact," said Amar Kapadia, Co-founder and CEO of Aarna.ml.
Ahammune Biosciences, based in Pune, raised $5 million in a Series A round led by pi Ventures. Other investors include Capital2B, Colossa Ventures, and Ideaspring Capital. This brings Ahammune's total funding to $8 million.
The funds will support Phase II clinical trials of Ahammune’s lead drug candidate for vitiligo, a skin condition. The company’s small molecule drug aims to stop the spread of vitiligo patches and help skin cells produce more color, leading to repigmentation.
Ahammune is also developing treatments for other skin diseases. "We aim to create cost-effective solutions for unmet needs in dermatology," said Parul Ganju, Co-founder and CEO of Ahammune.
Both Aarna.ml and Ahammune Biosciences are advancing cutting-edge solutions in their fields. Aarna.ml is focused on making GPU management easier for AI workloads, while Ahammune is pushing forward innovative skin disease therapies. Their latest funding rounds will help them grow and make a greater impact in their industries.